To study the benefits of the drug named Dapagliflozin in the Treatment of Diastolic Heart failure
- Conditions
- Health Condition 1: I00-I99- Diseases of the circulatory system
- Registration Number
- CTRI/2023/12/060807
- Lead Sponsor
- DrSubbiah
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
All patients aged more than 18 years of age diagnosed with Diastolic Heart failure are included
Diastolic Heart failure patients under treatment with either Dapagliflozin 10 mg or Telmisartan 40mg
LVEF > 45% documented by echocardiography
Patients with systolic Heart failure with EF < 45%
Uncontrolled Hypertension with systolic
BP >140 mmhg or Diastolic Bp >90 mmhgare excluded
Uncontrolled Diabetis mellitus with FBS >125 mg/dl or PPBS >200 mg/dl are excluded
Patients who need step up treatment in Baseline Regimen dosage for Hypertension or Diabetes mellitus during course of study are excluded
Patients who develop acute exacerbation or symptoms of congestive HF or those who need treatment with Diuretics during course of study are excluded
Presence of cardiomyopathy due to infiltrative disorders- amyloidosis, sarcoidosis are excluded
Dyspnea due to primary lung disorder
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method